Literature DB >> 33118529

SARS-CoV-2 and HIV: Epidemiology, Treatment, and Lessons Learned from HIV.

Amanda D Castel1, Brittany Wilbourn1, Manya Magnus1, Alan E Greenberg1.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of COVID-19, was first detected in China in December 2019 and has rapidly spread throughout the world. Globally, the impact of COVID-19 has been severe with more than half a million deaths over 6 months; in contrast, the HIV pandemic has resulted in over 32 million deaths worldwide over 40 years. This paper reviews the current epidemiology of COVID-19, summarizes its relationship to HIV, identifies synergies in our response, and suggests actions that can be taken to curtail the spread of COVID-19 among persons living with HIV (PLWH). Our understanding of the epidemiology, clinical presentation, prevention, and treatment of COVID-19 has evolved rapidly as they did with HIV. Epidemiologically, there are similarities between the two viruses including asymptomatic spread, disproportionate impact on persons of color, need for rapid diagnostic testing, and lack of a cure or vaccine. PLWH do not appear generally to have an increased incidence of COVID-19 infection or a more severe course of disease. Clinical trials to identify potential treatment and prevention options for COVID-19 have included antiretrovirals used to treat HIV that have not been efficacious. Public health responses overlap between the two pandemics including the need for behavior change and containment strategies such as contact tracing. As the SARS-CoV-2 pandemic evolves, the path forward to controlling, preventing, and treating COVID-19 can be informed by lessons learned from HIV as we seek to control the spread of both viral pandemics. Copyright:
© 2020 Permanyer.

Entities:  

Keywords:  COVID-19; Epidemiology; HIV; Pandemic; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 33118529     DOI: 10.24875/AIDSRev.20000070

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  6 in total

1.  Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect.

Authors:  Sora Yasri; Viroj Wiwanitki
Journal:  Int J Biochem Mol Biol       Date:  2022-02-15

Review 2.  HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups.

Authors:  Daniel K Nomah; Juliana Reyes-Urueña; Josep Ma Llibre; Juan Ambrosioni; Fabiana S Ganem; José Ma Miró; Jordi Casabona
Journal:  Curr HIV/AIDS Rep       Date:  2021-12-10       Impact factor: 5.071

Review 3.  Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway.

Authors:  Shuvomoy Banerjee; Xinyu Wang; Shujuan Du; Caixia Zhu; Yuping Jia; Yuyan Wang; Qiliang Cai
Journal:  J Med Virol       Date:  2022-05-09       Impact factor: 20.693

4.  Non-HIV-related comorbidities and uncontrolled HIV replication are independent factors increasing the odds of hospitalization due to COVID-19 among HIV-positive patients in Poland.

Authors:  Justyna D Kowalska; Martyna Lara; Maria Hlebowicz; Elżbieta Mularska; Elżbieta Jabłonowska; Ewa Siwak; Alicja Wandałowicz; Magdalena Witak-Jędra; Anita Olczak; Monika Bociąga-Jasik; Magdalena Suchacz; Justyna Stempkowska-Rejek; Piotr Wasilewski; Miłosz Parczewski
Journal:  Infection       Date:  2022-07-27       Impact factor: 7.455

Review 5.  HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups.

Authors:  D K Nomah; J Reyes-Urueña; J M Llibre; J Ambrosioni; F S Ganem; J M Miró; J Casabona
Journal:  Curr HIV/AIDS Rep       Date:  2022-02-03       Impact factor: 5.495

6.  A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV.

Authors:  Maria L Alcaide; Nicholas F Nogueira; Ana S Salazar; Emily K Montgomerie; Violeta J Rodriguez; Patricia D Raccamarich; Irma T Barreto; Angela McGaugh; Mark E Sharkey; Alejandro M Mantero; Allan E Rodriguez; Laura Beauchamps; Deborah L Jones
Journal:  Front Med (Lausanne)       Date:  2022-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.